Literature DB >> 22907355

Humanization by CDR grafting and specificity-determining residue grafting.

Jin Hong Kim1, Hyo Jeong Hong.   

Abstract

Humanized antibodies are constructed by CDR grafting, while retaining those murine framework residues that influence the antigen-binding activity. To reduce the immunogenicity of CDR-grafted humanized antibodies, the murine content in the CDR-grafted humanized antibodies is minimized through SDR grafting. Within each CDR, there are more variable positions that are directly involved in the interaction with antigen, i.e., specificity-determining residues (SDRs), whereas there are more conserved residues that maintain the conformations of CDRs loops. SDRs may be identified from the 3D structure of the antigen-antibody complex and/or the mutational analysis of the CDRs. An SDR-grafted humanized antibody is constructed by grafting the SDRs and the residues maintaining the conformations of the CDRs onto human template, and its immunogenic potential is evaluated by measuring the reactivity to the sera from patients who had been immunized with the parental antibody.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22907355     DOI: 10.1007/978-1-61779-974-7_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  12 in total

1.  Design and Generation of Humanized Single-chain Fv Derived from Mouse Hybridoma for Potential Targeting Application.

Authors:  Kannika Khantasup; Warangkana Chantima; Chak Sangma; Kanokwan Poomputsa; Tararaj Dharakul
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-12

2.  Non-covalent carriage of anticancer agents by humanized antibody trastuzumab.

Authors:  Arpita Yadav; Sweta Sharma; Veejendra Kumar Yadav
Journal:  J Mol Model       Date:  2016-04-25       Impact factor: 1.810

3.  Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline.

Authors:  Ivelin S Georgiev; Rebecca S Rudicell; Kevin O Saunders; Wei Shi; Tatsiana Kirys; Krisha McKee; Sijy O'Dell; Gwo-Yu Chuang; Zhi-Yong Yang; Gilad Ofek; Mark Connors; John R Mascola; Gary J Nabel; Peter D Kwong
Journal:  J Immunol       Date:  2014-01-03       Impact factor: 5.422

4.  Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins.

Authors:  Jared L Spidel; Earl F Albone; Xin Cheng; Benjamin Vaessen; Sara Jacob; Andrew Z Milinichik; Arielle Verdi; J Bradford Kline; Luigi Grasso
Journal:  MAbs       Date:  2017-05-25       Impact factor: 5.857

5.  SARS-CoV-2 neutralizing antibody development strategies.

Authors:  Bertan Koray BalcioĞlu; Melis Denİzcİ ÖncÜ; Hasan Ümit ÖztÜrk; Fatıma YÜcel; Filiz Kaya; Müge Serhatli; Hivda ÜlbeĞİ Polat; Şaban Tekİn; Aylin Özdemİr Bahadir
Journal:  Turk J Biol       Date:  2020-06-21

6.  Design and Construction of a Novel Humanized Single-Chain Variable-Fragment Antibody Against the Tumor Necrosis Factor Alpha.

Authors:  Davoud Farajzadeh; Sadigheh Karimi-Gharigh; Parisa Jalali-Kondori; Siavoush Dastmalchi
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

Review 7.  Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers.

Authors:  Kyusang Hwang; Jin Hwan Yoon; Ji Hyun Lee; Sukmook Lee
Journal:  Biomedicines       Date:  2021-01-05

8.  Humanized Chimeric Antigen Receptor (CAR) T cells.

Authors:  Pouya Safarzadeh Kozani; Pooria Safarzadeh Kozani; Roddy S O'Connor
Journal:  J Cancer Immunol (Wilmington)       Date:  2021

9.  Immune Regulatory 1 Cells: A Novel and Potent Subset of Human T Regulatory Cells.

Authors:  Nicolas Krause; Jörg Mengwasser; Elpida Phithak; Francisca Beato; Marc Appis; Edgar Louis Milford; Johan Pratschke; Igor Sauer; Anja Kuehl; Arndt Vogel; Michael Goodyear; Linda Hammerich; Frank Tacke; Johanna Faith Haas; Tobias Müller; Nalan Utku
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

Review 10.  Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics.

Authors:  Anne S De Groot; Frances Terry; Leslie Cousens; William Martin
Journal:  Expert Rev Clin Pharmacol       Date:  2013-11       Impact factor: 5.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.